Inflammatory bowel disease: towards a personalized medicine

The management of inflammatory bowel disease (IBD) has been transformed over the last two decades by the arrival of tumor necrosis factor (TNF) antagonist agents. Recently, alternative drugs have been approved, directed at leukocyte-trafficking molecules (vedolizumab) or other inflammatory cytokines...

Descripción completa

Detalles Bibliográficos
Autores principales: Flamant, Mathurin, Roblin, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784543/
https://www.ncbi.nlm.nih.gov/pubmed/29383027
http://dx.doi.org/10.1177/1756283X17745029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784543/
https://www.ncbi.nlm.nih.gov/pubmed/29383027
http://dx.doi.org/10.1177/1756283X17745029

Ejemplares similares